Complement Inhibition in the Treatment of SLE-Associated Thrombotic Thrombocytopenic Purpura.
作者信息
Boneparth Alexis, Moorthy L Nandini, Weiss Lynne, Rajasekhar Hariprem, Murphy Susan, Drachtman Richard A
机构信息
Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
出版信息
Glob Pediatr Health. 2015 Jan 30;2:2333794X15570150. doi: 10.1177/2333794X15570150. eCollection 2015.
Abstract
摘要
相似文献
1
Complement Inhibition in the Treatment of SLE-Associated Thrombotic Thrombocytopenic Purpura.
Glob Pediatr Health. 2015 Jan 30;2:2333794X15570150. doi: 10.1177/2333794X15570150. eCollection 2015.
2
Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.
Haematologica. 2016 Nov;101(11):1319-1326. doi: 10.3324/haematol.2016.149021. Epub 2016 Aug 4.
3
Diclofenac-induced thrombotic thrombocytopenic purpura with concomitant complement dysregulation: a case report and review of the literature.
J Med Case Rep. 2019 Jun 23;13(1):190. doi: 10.1186/s13256-019-2097-5.
4
Thrombotic thrombocytopenic purpura preceding systemic lupus erythematosus.
Ann Rheum Dis. 1992 Mar;51(3):396-8. doi: 10.1136/ard.51.3.396.
5
Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review.
Clin Rheumatol. 2022 Aug;41(8):2561-2569. doi: 10.1007/s10067-022-06155-6. Epub 2022 May 7.
6
Risk factors and clinical profile of thrombotic thrombocytopenic purpura in systemic lupus erythematosus patients. Is this a distinctive clinical entity in the thrombotic microangiopathy spectrum?: a case control study.
Thromb Res. 2014 Nov;134(5):1020-7. doi: 10.1016/j.thromres.2014.09.005. Epub 2014 Sep 16.
7
Successful treatment of refractory thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus with combination of plasma exchange and low-dose rituximab.
Lupus. 2020 Dec;29(14):1961-1967. doi: 10.1177/0961203320953473. Epub 2020 Aug 24.
8
Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study.
Orphanet J Rare Dis. 2020 Aug 28;15(1):225. doi: 10.1186/s13023-020-01510-9.
9
Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases.
Ann Intern Med. 1998 Apr 1;128(7):541-4. doi: 10.7326/0003-4819-128-7-199804010-00004.
10
Thrombotic thrombocytopenic purpura in a girl with systemic lupus erythematosus.
J Rheumatol. 1980 Sep-Oct;7(5):727-9.
引用本文的文献
1
Systemic lupus erythematosus presenting as thrombotic thrombocytopaenic purpura in a child: a diagnostic challenge.
BMJ Case Rep. 2020 Sep 2;13(9):e232002. doi: 10.1136/bcr-2019-232002.
2
Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.
Rheumatol Int. 2017 Aug;37(8):1249-1255. doi: 10.1007/s00296-017-3686-5. Epub 2017 Mar 3.
本文引用的文献
1
Diagnosis and management of complement mediated thrombotic microangiopathies.
Blood Rev. 2014 Mar;28(2):67-74. doi: 10.1016/j.blre.2014.01.003. Epub 2014 Jan 31.
2
Eculizumab in atypical hemolytic-uremic syndrome.
N Engl J Med. 2013 Oct 3;369(14):1379-80. doi: 10.1056/NEJMc1308826.
3
Fatal refractory thrombotic thrombocytopenic purpura complicating systemic lupus erythematosus.
J Clin Rheumatol. 2013 Oct;19(7):412-4. doi: 10.1097/RHU.0b013e3182a703bf.
4
Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab.
Am J Kidney Dis. 2013 Feb;61(2):289-99. doi: 10.1053/j.ajkd.2012.07.028. Epub 2012 Nov 7.
5
Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura.
Br J Haematol. 2012 Jun;157(6):772-4. doi: 10.1111/j.1365-2141.2012.09084.x. Epub 2012 Mar 13.
6
Complement activation in thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2012 May;10(5):791-8. doi: 10.1111/j.1538-7836.2012.04674.x.
7
Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: the role of ADAMTS13.
Rheumatology (Oxford). 2011 May;50(5):824-9. doi: 10.1093/rheumatology/keq395. Epub 2010 Dec 11.
8
Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases.
Thromb Haemost. 2009 Aug;102(2):371-8. doi: 10.1160/TH08-12-0825.
9
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies.
Thromb Haemost. 2005 Mar;93(3):443-52. doi: 10.1160/TH04-07-0450.
10
Molecular mechanisms in thrombotic thrombocytopenic purpura.
Semin Thromb Hemost. 2004 Oct;30(5):549-57. doi: 10.1055/s-2004-835675.
Zotero 插件